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INTRODUCTION
Interferon assay. Serum samples were kept frozen at -80°C after processing, and then sent to Hoffman-La Roche, Inc., laboratories in Nutley, NJ, on dry ice. PEGIFN concentrations 117 were determined using a sandwich ELISA, in which capture antibody (affinity purified rabbit 118 polyclonal anti-PEG-IFN) was coated onto micro-titer plates. Serum samples were added to the 119 plate and incubated. The plate was washed and detection antibody (mouse monoclonal anti-PEG) 120 was added and then further incubated. The plate was washed again and peroxidase conjugated 121 goat anti-mouse IgM) was added and incubated. After a final wash, a substrate solution was 122 added. Color developed in proportion to the amount of PEGIFN present in the sample. This 123 assay has a range of 250-5,000 pg/mL. The intra-batch precision was 2.5-8.4%, and the accuracy 124 was -5.5-13.2%. The inter-batch precision was 11.7-16.6% and the accuracy 0.4-9.0%. 
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Roche Pharmaceuticals measured interferon levels for this study. is clearly demonstrated in the literature and in also shown for these data in Table 3 . 
473
The time to viral load suppression was calculated in days. Patients who were discontinued 474 therapy due to therapy were censored at the time when therapy was discontinued. 
